secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066376
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport Therapeutics Q1 net loss $24.1M; RAP-219 epilepsy trial on track for Q3 2025 data
--------------------------------------------------------------------------------

- Net loss $24.1M in Q1 2025 vs $22.7M prior year; R&D expenses rose to $19.6M from $12.5M.
- Cash & short-term investments $285.4M at Mar 31, 2025 (down from $305.3M Dec 31, 2024); runway through end of 2026.
- RAP-219 Phase 2a refractory focal epilepsy topline results expected Q3 2025.
- RAP-219 Phase 2a bipolar mania trial to start Q3 2025; topline data expected H1 2027.
- Dr. Jeffrey Sevigny appointed CMO; Investor & Analyst Day scheduled June 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/0000950170-25-066376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025066376/rapp-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer